On the 7th of August 2014, Tekmira Pharmaceuticals Announced That the FDA has Allowed Potential Use of Their Experimental Ebola Drug on Infected Patients

Tekmira’s Lipid Nanoparticle (LNP) Technology Targeting Ebola Like Virus Highlighted in Scientific Publication

Data From Animal Model Demonstrates Complete Protection Three Days After Infection August 20th, 2014 Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced the publication of data in a peer-reviewed scientific journal which highlights positive results in an animal model of Marburg virus infection enabled by Tekmira’s lipid nanoparticle (LNP) technology. Tekmira, along with …

On the 7th of August 2014, Tekmira Pharmaceuticals Announced That the FDA has Allowed Potential Use of Their Experimental Ebola Drug on Infected Patients

FDA Modifies Tekmira’s TKM-Ebola Clinical Hold to Partial Hold

August 7th, 2014 -FDA Modifies Tekmira’s TKM-Ebola Clinical Hold to Partial Hold -Enabling Use of Tekmira’s Investigational Therapeutic in Ebola-Infected Patients ekmira Pharmaceuticals Corporation (TKMR) (TKM.TO), a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Food & Drug Administration (FDA) has verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola Investigational New …